BTCS Inc
BTCS
Digihost Technology
DGHI
CATHEDRA BITCOIN INC
CBTTF
Bakkt Holdings
BKKT
Abits
ABTS
US Stock MarketDetailed Quotes
TIL Instil Bio
- 20.9700
- -0.4500-2.10%
Close Jan 17 16:00 ET
- 20.9700
- 0.00000.00%
Post 16:31 ET
136.85MMarket Cap-1.81P/E (TTM)
21.3500High20.6300Low36.64KVolume21.3100Open21.4200Pre Close769.87KTurnover1.53%Turnover RatioLossP/E (Static)6.53MShares92.000052wk High0.78P/B50.13MFloat Cap9.580052wk Low--Dividend TTM2.39MShs Float589.8000Historical High--Div YieldTTM3.36%Amplitude6.0600Historical Low21.0110Avg Price1Lot Size
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Instil Bio Stock Forum
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Tuesday, 14th January at 7:00 am
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China
ImmuneOnco announced initial clinical data from the 1L advanced NSCLC trial in China is expected as early as 2H 2025
Instil is target...
keep 👀 $Instil Bio (TIL.US)$
Baird's optimism is driven by promising developments in Instil’s PD-L1xVEGF bispecific antibody, especially following positive data from peers like Akeso and Summit. Analysts believe this drug class has strong potentia...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
No comment yet